Skip to main content
Equibles
PSNL logo

PSNL · Personalis, Inc. · Documents

Track PSNL — free

Use PSNL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PSNL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$15.71 -0.15 (-0.95%) At close · Nov 13 Play latest call Q1 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$1.70B
Shares
108.40M
Volume · Nov 13 2.8M Avg daily vol (3M) 2.7M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $69.65M down 17.7% 10-K filed Feb 26, 2026 Quarterly report FY2026 Q3 Revenue $25.6M up 76.6% 10-Q filed Nov 4, 2026 Latest results Revenue growth and higher clinical testing 8-K filed Nov 4, 2026 Earnings call Q1 2026 earnings call Held May 7, 2026
2026
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Tempus merger vote scheduled for November 30, 2026

Personalis entered into a merger agreement with Tempus on July 20, 2026 and filed its definitive proxy statement/prospectus on October 21, 2026. Stockholders are scheduled to vote on the transaction on November 30, 2026.

Revenue $25.6M ▲ 76.6% Net loss $33.8M Diluted EPS -$0.32
Read from the MD&A section
4 source passages
On July 20, 2026, we entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Tempus (sometimes referred to as Parent), Aviary Development, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub I”) and Toucan Development, LLC, a Nevada limited liability company and a wholly owned subsidiary of Parent (“Merger Sub II”). Merger Sub I will be merged with and into Personalis (the “First Merger”), with Personalis surviving the First Merger as a wholly owned subsidiary of Parent (the “First Surviving Corporation”). On October 21, 2026, we filed our definitive proxy statement/prospectus relating to the Merger. The special meeting of our stockholders to consider and vote on the adoption of the Merger Agreement is scheduled for November 30, 2026. Open the document at this passage
Nov 4
Current report 8-K
Revenue growth and higher clinical testing

Personalis reported results for the third quarter ended September 30, 2026. Total revenue was $25.6 million versus $14.5 million, clinical revenue was $4.4 million, and clinical test volume was 13,157; cash, cash equivalents and short-term investments totaled approximately $190.6 million.

Financial results
4 source passages
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the third quarter ended September 30, 2026. Quarterly Revenue: Total revenue of $25.6 million compared with $14.5 million, primarily driven by growth in clinical test revenue, as well as core revenue from increased population sequencing and higher pharma testing services. Clinical Revenue: Clinical test revenue of $4.4 million compared with $0.4 million, resulting from the increase in test volume and also a full quarter of Medicare covered IO test volume, in addition to revenue from breast and lung cancer covered tests; delivered 13,157 clinical tests compared with 4,388. Cash Position: Ended the quarter with approximately $190.6 million in cash, cash equivalents, and short-term investments. Open the document at this passage
Oct 21
Proxy statement DEFM14A
Proxy statement

Personalis stockholders will vote on November 30, 2026 on Tempus AI, Inc.’s proposed merger, under which the company will become a wholly owned subsidiary; its board unanimously recommends approval.

Read from the first part of this long document
Oct 6
Current report 8-K Events of Oct 2
Other events

Personalis’ proposed merger with Tempus AI advanced after the HSR waiting period expired at 11:59 p.m., Eastern time, on October 2, 2026; closing remains subject to stockholder approval and other closing conditions.

Aug 20
Current report 8-K
Other events AI summary on its way
Aug 4
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $22.36M ▲ 30.0% Net loss $31.68M Diluted EPS -$0.30
May 20
Current report 8-K Events of May 19
Other events AI summary on its way
May 13
Current report 8-K Events of May 12
Other events AI summary on its way
May 7
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $15.47M ▼ 24.9% Net loss $30.03M Diluted EPS -$0.29
Apr 2
Proxy statement DEF 14A Meeting May 12, 2026
Proxy statement AI summary on its way
Feb 26
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $69.65M ▼ 17.7% Net loss $81.27M Diluted EPS -$0.91
2025
Feb 27
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $84.61M ▲ 15.2% Net loss $81.28M Diluted EPS -$1.37
2024
Showing 1–50 of 155 documents
Key facts CIK 1527753 CUSIP 71535D106 13F (30d) 147 filings 126 filers Visit website Investor relations